Kate Broderick: INO 4800 A DNA based vaccine against COVID 19

In this talk, Dr Broderick introduces us to the INO4800 SARSCoV2 DNA vaccine and shares Phase I and II clinical trial data. The vaccine is shown to induce broad antibody and persistent CD8 T cell responses (including T cell responses targeting Variants of Concern). Kate Broderick received her from the University of Glasgow, Scotland, and conducted postdoctoral research at the University of California, San Diego. She joined INOVIO in 2006, where she currently leads a diverse research group focused on enhanced delivery techniques for genebased therapeutics as the Senior Vice President, Preclinical R D. She is a coinventor on multiple patents related to DNA vaccine delivery and has served as a principal investigator on grants, awards, and contracts from leading government agencies and notforprofit organizations, including the Bill and Melinda Gates Foundation, the National Institutes of Health, the U. S. Department of Defense, the Small Business Innovation Research program, and including